NASDAQ:GLSI

Greenwich LifeSciences (GLSI) Stock Forecast, Price & News

$10.97

+0.30 (+2.81%)

(As of 06/2/2023 ET)

Compare

Today's Range: $10.31
▼
$11.04
50-Day Range: $10.35
▼
$14.11
52-Week Range: $6.82
▼
$21.50

Volume: 47,710 shs
Average Volume: 17,001 shs
Market Capitalization: $140.96 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $38.00

Greenwich LifeSciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 246.4% Upside
$38.00 Price Target
Short Interest: Healthy
6.76% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$126,002 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

599th out of 983 stocks

Pharmaceutical Preparations Industry

298th out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
Greenwich LifeSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $38.00, Greenwich LifeSciences has a forecasted upside of 246.4% from its current price of $10.97.
Amount of Analyst Coverage
Greenwich LifeSciences has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
6.76% of the float of Greenwich LifeSciences has been sold short.
Short Interest Ratio / Days to Cover
Greenwich LifeSciences has a short interest ratio ("days to cover") of 5.6.
Change versus previous month
Short interest in Greenwich LifeSciences has recently decreased by 21.66%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Greenwich LifeSciences does not currently pay a dividend.
Dividend Growth
Greenwich LifeSciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GLSI.

0.6

News and Social Media Coverage

Search Interest
Only 1 people have searched for GLSI on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
MarketBeat Follows
4 people have added Greenwich LifeSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Greenwich LifeSciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $126,002.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
52.14% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 6.18% of the stock of Greenwich LifeSciences is held by institutions.

0.0

Earnings and Valuation

Price to Book Value per Share Ratio
Greenwich LifeSciences has a P/B Ratio of 12.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Greenwich LifeSciences (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Receive GLSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

GLSI Stock News Headlines

May 20, 2023 | americanbankingnews.com

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Purchases 1,000 Shares

April 22, 2023 | americanbankingnews.com

Snehal Patel Acquires 2,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

June 3, 2023 | Behind the Markets (Ad)

How A.I. Could Make Most 21st Century Diseases EXTINCT

On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...

April 19, 2023 | usnews.com

East Greenwich High School

April 19, 2023 | usnews.com

Greenwich Junior-Senior High School

April 19, 2023 | americanbankingnews.com

Short Interest in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Increases By 43.2%

April 13, 2023 | americanbankingnews.com

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson Acquires 1,000 Shares

April 13, 2023 | americanbankingnews.com

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Acquires 5,000 Shares of Stock

June 3, 2023 | Behind the Markets (Ad)

WARNING to all American Investors

China's sneaky plan could wipe out your retirement - in a single morning. Learn how to protect yourself here>>>

April 12, 2023 | greenwichtime.com

In Photos: Greenwich turns out for an Easter Egg Hunt and festival courtesy of the Historical Society

April 12, 2023 | americanbankingnews.com

HC Wainwright Trims Greenwich LifeSciences (NASDAQ:GLSI) Target Price to $38.00

April 10, 2023 | msn.com

HC Wainwright & Co. Reiterates Greenwich Lifesciences (GLSI) Buy Recommendation

April 10, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Greenwich LifeSciences (GLSI)

April 9, 2023 | greenwichtime.com

Greenwich BET OKs $482M budget: Rink replacement money, yes; Cos Cob Library renovation, no

April 9, 2023 | greenwichtime.com

Florida man now second person arrested in $64K email scam targeting Greenwich woman

April 8, 2023 | greenwichtime.com

Stamford man accused of 2021 Greenwich sexual assault expected to make plea in May, police say

April 6, 2023 | finance.yahoo.com

Insiders own 39% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares but retail investors control 42% of the company

April 2, 2023 | greenwichtime.com

Greenwich Hospital raises $4 million for behavioral health expansion

April 1, 2023 | greenwichtime.com

Parents, others tell Greenwich BET there's 'no rationale for the nickel and diming' on school projects

March 20, 2023 | greenwichtime.com

Greenwich High's long-debated $3.3 million entryway vestibule project OKed by school board

March 19, 2023 | greenwichtime.com

In Photos: Greenwich Public Schools students' art featured at Bendheim Gallery

March 19, 2023 | greenwichtime.com

Expanded clubhouse proposed at Greenwich apartment complex once target of lawsuit

March 17, 2023 | greenwichtime.com

Family mourns Greenwich pedestrian who died after being struck by a car as devoted mother, dog lover

March 12, 2023 | greenwichtime.com

Greenwich man turns lost story by 'Black Adam' co-creator and 'Superman' writer into graphic novel

March 12, 2023 | greenwichtime.com

Greenwich registrars (opinion): There is nothing 'lurking underneath' the grant

March 7, 2023 | greenwichtime.com

Opinion: Why we can’t have nice things in Greenwich

March 4, 2023 | greenwichtime.com

Greenwich officials spar over new Central Middle School price during budget talks

See More Headlines

GLSI Price History

30 days | 90 days | 365 days | Advanced Chart

GLSI Company Calendar

Today: 6/03/2023
Next Earnings (Estimated): 8/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GLSI
CUSIP: N/A
CIK: 1799788
Web: www.greenwichlifesciences.com
Phone: 832-819-3232
Fax: N/A
Employees: 3
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $38.00
High Stock Price Forecast: $38.00
Low Stock Price Forecast: $38.00
Forecasted Upside/Downside: +246.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,820,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -55.73%
Return on Assets: -54.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 50.47
Quick Ratio: 50.47

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.91 per share
Price / Book: 12.05

Miscellaneous

Outstanding Shares: 12,850,000
Free Float: 6,149,000
Market Cap: $140.96 million
Optionable: Not Optionable
Beta: 0.89

Key Executives

Mr. Snehal S. Patel (Age 60)
CEO, CFO & Director
Comp: $925k

Mr. Eric Rothe (Age 48)
Founder & Independent Director

Dr. Frank Joseph Daugherty M.D. (Age 73)
Chief Medical Officer & Director

Dr. Jaye L. Thompson Ph.D. (Age 57)
VP of Clinical & Regulatory Affairs

Dr. Christine T. Fischette Ph.D. (Age 72)
VP of Bus. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GLSI Stock - Frequently Asked Questions

Should I buy or sell Greenwich LifeSciences stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Greenwich LifeSciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GLSI shares.
View GLSI analyst ratings or view top-rated stocks.
What is Greenwich LifeSciences' stock price forecast for 2023?: 1 Wall Street research analysts have issued 12 month price targets for Greenwich LifeSciences' shares. Their GLSI share price forecasts range from $38.00 to $38.00. On average, they anticipate the company's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 246.4% from the stock's current price.
View analysts price targets for GLSI or view top-rated stocks among Wall Street analysts.
How have GLSI shares performed in 2023?: Greenwich LifeSciences' stock was trading at $15.20 at the start of the year. Since then, GLSI shares have decreased by 27.8% and is now trading at $10.97.
View the best growth stocks for 2023 here.
When is Greenwich LifeSciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our GLSI earnings forecast.
When did Greenwich LifeSciences IPO?: (GLSI) raised $7 million in an initial public offering on Friday, September 25th 2020. The company issued 1,300,000 shares at $5.75 per share. Aegis Capital acted as the underwriter for the IPO.

What is Greenwich LifeSciences' stock symbol?: Greenwich LifeSciences trades on the NASDAQ under the ticker symbol "GLSI."
Who are Greenwich LifeSciences' major shareholders?: Greenwich LifeSciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (0.44%), Renaissance Technologies LLC (0.40%), Susquehanna International Group LLP (0.29%), HRT Financial LP (0.14%), Jane Street Group LLC (0.14%) and Citigroup Inc. (0.10%). Insiders that own company stock include David Mcwilliams, Frank Joseph Daugherty, Jaye Thompson, Kenneth Hallock and Snehal Patel.
View institutional ownership trends.
How do I buy shares of Greenwich LifeSciences?: Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Greenwich LifeSciences' stock price today?: One share of GLSI stock can currently be purchased for approximately $10.97.
How much money does Greenwich LifeSciences make?: Greenwich LifeSciences (NASDAQ:GLSI) has a market capitalization of $140.96 million.
How can I contact Greenwich LifeSciences?: The official website for the company is www.greenwichlifesciences.com. The company can be reached via phone at 832-819-3232 or via email at info@greenwichlifesciences.com.

This page (NASDAQ:GLSI) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial